Research Papers:

FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases

Yin Xu, Kaiqiang Wang and Qin Yu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:70080-70091. https://doi.org/10.18632/oncotarget.12148

Metrics: PDF 2610 views  |   HTML 2648 views  |   ?  


Yin Xu1, Kaiqiang Wang1, Qin Yu1

1Department of Oncological Sciences Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Correspondence to:

Qin Yu, email: [email protected]

Keywords: FRMD6, glioblastoma, receptor tyrosine kinase, hippo signaling pathway, c-Met

Received: March 10, 2016     Accepted: September 02, 2016     Published: September 20, 2016


FRMD6 is an Ezrin/Radixin/Moesin (ERM) family protein and a human homologue of Drosophila expanded (ex). Ex functions in parallel of Drosophila merlin at upstream of the Hippo signaling pathway that controls proliferation, apoptosis, tissue regeneration, and tumorigenesis. Even though the core kinase cascade (MST1/2-Lats1/2-YAP/TAZ) of the Hippo pathway has been well established, its upstream regulators are not well understood. Merlin promotes activation of the Hippo pathway. However, the effect of FRMD6 on the Hippo pathway is controversial. Little is known about how FRMD6 functions and the potential role of FRMD in gliomagenesis and glioblastoma (GBM) progression. We demonstrate for the first time that FRMD6 is down-regulated in human GBM cells and tissues and that increased FRMD6 expression inhibits whereas FRMD6 knockdown promotes GBM cell proliferation/invasion in vitro and GBM growth/progression in vivo. Furthermore, we demonstrate that unlike increased expression of merlin, which enhances the stress induced activation of the Hippo pathway, increased FRMD6 expression displays little effect on the pathway. In contrast, we show that FRMD6 inhibits activation of a couple of receptor tyrosine kinases (RTKs) including c-Met and PDGFR and their downstream Erk and AKT kinases. Moreover, we show that expression of constitutively active c-Met, the TPR-Met fusion protein, largely reverses the anti-GBM effect of FRMD6 in vivo, suggesting that FRMD6 functions at least partially through inhibiting activity of RTKs especially c-Met. These results establish a novel function of FRMD6 in inhibiting human GBM growth and progression and uncover a novel mechanism by which FRMD6 exerts its anti-GBM activity.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12148